IL321098A - Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors - Google Patents

Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors

Info

Publication number
IL321098A
IL321098A IL321098A IL32109825A IL321098A IL 321098 A IL321098 A IL 321098A IL 321098 A IL321098 A IL 321098A IL 32109825 A IL32109825 A IL 32109825A IL 321098 A IL321098 A IL 321098A
Authority
IL
Israel
Prior art keywords
combination therapy
immune checkpoint
checkpoint inhibitors
binding
therapy involving
Prior art date
Application number
IL321098A
Other languages
Hebrew (he)
Original Assignee
Astellas Pharma Europe Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Europe Bv filed Critical Astellas Pharma Europe Bv
Publication of IL321098A publication Critical patent/IL321098A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL321098A 2022-12-14 2023-12-12 Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors IL321098A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263387403P 2022-12-14 2022-12-14
EP2023061047 2023-04-26
PCT/EP2023/085290 WO2024126457A1 (en) 2022-12-14 2023-12-12 Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors

Publications (1)

Publication Number Publication Date
IL321098A true IL321098A (en) 2025-07-01

Family

ID=89222231

Family Applications (1)

Application Number Title Priority Date Filing Date
IL321098A IL321098A (en) 2022-12-14 2023-12-12 Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors

Country Status (12)

Country Link
EP (1) EP4634224A1 (en)
JP (1) JP2026501506A (en)
KR (1) KR20250120305A (en)
CN (1) CN120418289A (en)
AR (1) AR131342A1 (en)
AU (1) AU2023393653A1 (en)
CL (1) CL2025001604A1 (en)
CO (1) CO2025009080A2 (en)
IL (1) IL321098A (en)
MX (1) MX2025006378A (en)
TW (1) TW202436336A (en)
WO (1) WO2024126457A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026033885A1 (en) * 2024-08-08 2026-02-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2

Family Cites Families (205)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2084987C (en) 1990-06-11 2007-02-13 Gilead Sciences, Inc. Nucleic acid ligands
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
JP2001523958A (en) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド CTLA-4 binding peptides for immunotherapy
DK2112166T3 (en) 1998-12-23 2019-02-04 Pfizer Human monoclonal antibodies to CTLA-4
EE05627B1 (en) 1998-12-23 2013-02-15 Pfizer Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
CA2383424C (en) 1999-08-23 2011-02-15 Gordon Freeman Novel b7-4 molecules and uses therefor
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
ATE240744T1 (en) 1999-10-28 2003-06-15 Hofbauer Reinhold USE OF CSF-1 INHIBITORS
EP3225632B1 (en) 1999-11-30 2020-05-06 Mayo Foundation for Medical Education and Research Antibodies binding to b7-h1, a novel immunoregulatory molecule
EP1261376A1 (en) 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
GB0100621D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
DK1507556T3 (en) 2002-05-02 2016-09-12 Wyeth Holdings Llc Calicheamicin derivative-carrier conjugates
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
PL216630B1 (en) 2002-10-17 2014-04-30 Genmab As Human monoclonal antibodies against cd20
DK1578446T3 (en) 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
ES2347241T3 (en) 2002-12-16 2010-10-27 Genentech, Inc. VARIATIONS OF IMMUNOGLOBULIN AND ITS USES.
CN1753912B (en) 2002-12-23 2011-11-02 惠氏公司 Anti-PD-1 antibodies and uses thereof
KR101420344B1 (en) 2003-07-02 2014-07-16 위니베르시따 디 제노바 Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
EP2292264A3 (en) 2003-07-24 2012-12-19 Innate Pharma Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
DK2287195T3 (en) 2004-07-01 2019-08-19 Innate Pharma PAN-KIR2DL NK-RECEPTOR ANTIBODIES AND USE IN DIAGNOSTICS AND THERAPY
SI1836225T1 (en) 2005-01-06 2012-06-29 Novo Nordisk As Kir-binding agents and methods of use thereof
WO2006072625A2 (en) 2005-01-06 2006-07-13 Novo Nordisk A/S Anti-kir combination treatments and methods
ES2720160T3 (en) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Human monoclonal antibodies against programmed death 1 (PD-1) and methods for treating cancer using antibodies directed against PD-1 alone or together with other immunotherapeutic substances
EA019344B1 (en) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Human monoclonal antibodies to programmed death ligand 1 (pd-l1) and uses thereof
JP5419067B2 (en) 2005-10-14 2014-02-19 イナート・ファルマ・ソシエテ・アノニム Compositions and methods for treating proliferative disorders
GB0521991D0 (en) 2005-10-28 2005-12-07 Univ Dundee Siglec-9 binding agents
CN101578113B (en) 2007-01-11 2015-04-22 诺和诺德公司 Anti-KIR antibodies, formulations, and uses thereof
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
JP5191537B2 (en) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー Antibodies against human programmed death receptor PD-1
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
CN101952317B (en) 2008-01-24 2015-07-22 诺沃-诺迪斯克有限公司 Humanized anti-human NKG2A monoclonal antibody
EP2242773B1 (en) 2008-02-11 2017-06-14 Cure Tech Ltd. Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme BINDING PROTEINS WITH PD-1
DE102008036127A1 (en) 2008-08-01 2010-02-04 Emitec Gesellschaft Für Emissionstechnologie Mbh Method for operating an exhaust system with lambda control
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
EP2328920A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Targeted costimulatory polypeptides and methods of use to treat cancer
BRPI0919377A2 (en) 2008-09-26 2016-09-27 Dana Farber Cancer Inst Inc isolated antibody or antigen-binding fragment of the same, isolated nucleic acid, vector, host cell, pharmaceutical composition, method of producing said antibody or fragment, use thereof, and composition comprising said antibody or fragment
US8709411B2 (en) 2008-12-05 2014-04-29 Novo Nordisk A/S Combination therapy to enhance NK cell mediated cytotoxicity
HUE065752T2 (en) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-pd-l1 antibodies and their use to enhance t-cell function
ES2629337T3 (en) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Antibodies against PD-1 and antibodies against PD-L1 and uses thereof
EP2408818A1 (en) 2009-03-17 2012-01-25 Université de la Méditerranée Btla antibodies and uses thereof
EA201270228A1 (en) 2009-07-31 2012-09-28 Медарекс, Инк. FULLY HUMAN ANTIBODIES TO BTLA
CA2772204A1 (en) 2009-08-31 2011-03-03 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
PT2504364T (en) 2009-11-24 2017-11-14 Medimmune Ltd Targeted binding agents against b7-h1
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc Simultaneous inhibition of pd-l1/pd-l2
AU2010329934B2 (en) 2009-12-10 2015-05-14 F. Hoffmann-La Roche Ag Antibodies binding preferentially human CSF1R extracellular domain 4 and their use
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
MX2012010014A (en) 2010-03-05 2012-09-21 Hoffmann La Roche Antibodies against human csf-1r and uses thereof.
CA2789071C (en) 2010-03-05 2018-03-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
MX355418B (en) 2010-05-04 2018-04-18 Five Prime Therapeutics Inc Antibodies that bind csf1r.
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CA2818684C (en) 2010-11-22 2023-02-21 Innate Pharma Sa Nk cell modulating treatments and methods for treatment of hematological malignancies
JP6072771B2 (en) 2011-04-20 2017-02-01 メディミューン，エルエルシー Antibodies and other molecules that bind to B7-H1 and PD-1
TWI560200B (en) 2011-05-25 2016-12-01 Innate Pharma Sa Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
EA026924B1 (en) 2011-08-01 2017-05-31 Дженентек, Инк. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
EP2773651B1 (en) 2011-11-03 2020-12-23 The Trustees of the University of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
KR101981873B1 (en) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 Anti-pd-l1 antibodies and uses thereof
US10023643B2 (en) 2011-12-15 2018-07-17 Hoffmann-La Roche Inc. Antibodies against human CSF-1R and uses thereof
BR112014014181A2 (en) 2011-12-16 2017-06-13 Oncology Inst Of Southern Switzerland combination of inotuzumab and torisel ozogamycin for cancer treatment
EP2812355A4 (en) 2012-02-06 2016-03-02 Hoffmann La Roche COMPOSITIONS AND METHODS OF USING CSF1R INHIBITORS
AR090263A1 (en) 2012-03-08 2014-10-29 Hoffmann La Roche COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME
JP2015517490A (en) 2012-05-11 2015-06-22 ファイブ プライム セラピューティックス インコーポレイテッド Method of treating a condition using an antibody that binds colony stimulating factor 1 receptor (CSF1R)
US9212224B2 (en) 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
CN104736168B (en) 2012-05-31 2018-09-21 索伦托治疗有限公司 Antigen-binding protein that binds to PD-L1
RU2689760C2 (en) 2012-05-31 2019-05-30 Дженентек, Инк. Methods of treating cancer using pd-1 axis binding and vegf antagonists
UY34887A (en) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
SG10201906328RA (en) 2012-08-31 2019-08-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
KR102130865B1 (en) 2012-10-02 2020-08-05 브리스톨-마이어스 스큅 컴퍼니 Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
US9789182B2 (en) 2012-10-23 2017-10-17 Bristol-Myers Squibb Company Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
US9969789B2 (en) 2012-12-17 2018-05-15 Trillium Therapeutics Inc. Treatment of CD47+ disease cells with SIRP alpha-Fc fusions
AR093984A1 (en) 2012-12-21 2015-07-01 Merck Sharp & Dohme ANTIBODIES THAT JOIN LEGEND 1 OF SCHEDULED DEATH (PD-L1) HUMAN
CN105051069B (en) 2013-01-14 2019-12-10 Xencor股份有限公司 Novel heterodimeric proteins
BR112015020235A2 (en) 2013-02-28 2017-10-10 Univ Edinburgh biologically active fragment of csf-1 protein or a homologue thereof, nucleic acid, fusion protein, isolated nucleic acid, vector, host cell, fusion protein embodiment of the first aspect of the invention, composition, use of a fusion protein , method of treatment for an individual suffering from liver cancer and undergoing surgery, method of treatment for an individual undergoing liver transplant surgery, and, kit
WO2014165082A2 (en) 2013-03-13 2014-10-09 Medimmune, Llc Antibodies and methods of detection
SMT201700530T1 (en) 2013-03-14 2018-01-11 Bristol Myers Squibb Co Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
HRP20201113T1 (en) 2013-03-15 2020-10-30 Glaxosmithkline Intellectual Property Development Limited Anti-lag-3 binding proteins
KR102243062B1 (en) 2013-05-02 2021-04-21 아납티스바이오, 아이엔씨. Antibodies directed against programmed death-1 (pd-1)
US10005839B2 (en) 2013-05-17 2018-06-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antagonist of the BTLA/HVEM interaction for use in therapy
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
CN104250302B (en) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 The anti-antibody of PD 1 and its application
US20160271218A1 (en) 2013-06-27 2016-09-22 Mor Research Applications Ltd. Soluble ctla-4 molecules and derivatives thereof for treatment of minimal change disease
AU2014290069B2 (en) 2013-07-16 2019-01-03 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
EA035550B1 (en) 2013-08-01 2020-07-06 Юниверсите Католик Де Лувэн ANTIBODIES THAT BIND TO A COMPLEX OF hGARP/TGF-1 AND USE THEREOF
JP6623353B2 (en) 2013-09-13 2019-12-25 ベイジーン スウィッツァーランド ゲーエムベーハー Anti-PD-1 antibodies and their use for therapy and diagnosis
SI3508502T1 (en) 2013-09-20 2023-07-31 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
WO2015061668A1 (en) 2013-10-25 2015-04-30 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
US20160263087A1 (en) 2013-11-08 2016-09-15 Iteos Therapeutics Novel 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
US9126984B2 (en) 2013-11-08 2015-09-08 Iteos Therapeutics 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
MX375221B (en) 2013-11-25 2025-03-06 Famewave Ltd Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy
EP3082802B1 (en) 2013-12-03 2020-02-26 Iomet Pharma Ltd. Tryptophan-2,3-dioxygenase (tdo) and/or indolamine-2,3-dioxygenase (ido) inhibitors and their use
ES2746805T3 (en) 2013-12-12 2020-03-06 Shanghai hengrui pharmaceutical co ltd PD-1 antibody, antigen-binding fragment thereof and medical application thereof
EP4079321A1 (en) 2014-01-15 2022-10-26 Kadmon Corporation, LLC Immunomodulatory agents
US10711272B2 (en) 2014-01-21 2020-07-14 City Of Hope CTLA-4 aptamer siRNA species
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
TWI680138B (en) 2014-01-23 2019-12-21 美商再生元醫藥公司 Human antibodies to pd-l1
ES2716685T3 (en) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Antibody molecules for PD-1 and uses thereof
KR20160106762A (en) 2014-01-28 2016-09-12 브리스톨-마이어스 스큅 컴퍼니 Anti-lag-3 antibodies to treat hematological malignancies
EP3105225A1 (en) 2014-02-12 2016-12-21 iTeos Therapeutics Novel 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use
WO2015140717A1 (en) 2014-03-18 2015-09-24 Iteos Therapeutics Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
RS60878B1 (en) 2014-04-04 2020-11-30 Iomet Pharma Ltd Indole derivatives for use in medicine
ES2749098T3 (en) 2014-05-13 2020-03-19 Medimmune Ltd ANTI-B7-H1 and ANTI-CTLA-4 antibodies to treat non-small cell lung cancer
CA2947157A1 (en) 2014-05-13 2015-11-19 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
WO2015173764A1 (en) 2014-05-15 2015-11-19 Iteos Therapeutics Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
ES2753360T3 (en) 2014-05-29 2020-04-08 Spring Bioscience Corp Antibodies to PD-L1 and uses thereof
TWI693232B (en) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
KR102003754B1 (en) 2014-07-03 2019-07-25 베이진 엘티디 Anti-PD-L1 Antibodies and Their Use as Therapeutics and Diagnostics
BR112017000497B1 (en) 2014-07-11 2023-12-26 Ventana Medical Systems, Inc ISOLATED ANTIBODY, PROKARYOTIC HOST CELL, IMMUNOCONJUGATE AND METHOD FOR DETECTING THE PRESENCE OR LEVEL OF PD-L1 EXPRESSION
WO2016022630A1 (en) 2014-08-05 2016-02-11 Jiping Zha Anti-pd-l1 antibodies
JO3663B1 (en) 2014-08-19 2020-08-27 Merck Sharp & Dohme Anti-lag3 antibodies and antigen-binding fragments
GB201414730D0 (en) 2014-08-19 2014-10-01 Tpp Global Dev Ltd Pharmaceutical compound
RU2017105425A (en) 2014-08-28 2018-09-28 Академиш Зикенхёйс Лейден Х.О.Д.Н. Люмк ANTIBODY COMBINATIONS AGAINST CD94 / NKG2A AND / OR CD94 / NKG2B AND VACCINES
WO2016038064A1 (en) 2014-09-10 2016-03-17 Innate Pharma Cross reactive siglec antibodies
WO2016041947A1 (en) 2014-09-16 2016-03-24 Innate Pharma Treatment regimens using anti-nkg2a antibodies
UY36351A (en) 2014-10-14 2016-06-01 Novartis Ag ANTIBODY MOLECULES THAT JOIN PD-L1 AND USES OF THE SAME
AU2015341913B2 (en) 2014-11-03 2020-07-16 Iomet Pharma Ltd Pharmaceutical compound
GB201419579D0 (en) 2014-11-03 2014-12-17 Iomet Pharma Ltd Pharmaceutical compound
MX385320B (en) 2014-11-10 2025-03-18 Medimmune Ltd GROUP OF DIFFERENTIATION 73 (CD73) SPECIFIC BINDING MOLECULES AND THEIR USES.
TWI595006B (en) 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-PD-1 antibodies and methods of using same
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
MA41463A (en) 2015-02-03 2017-12-12 Anaptysbio Inc ANTIBODIES DIRECTED AGAINST LYMPHOCYTE ACTIVATION GEN 3 (LAG-3)
WO2016125017A1 (en) 2015-02-03 2016-08-11 Universite Catholique De Louvain Anti-garp protein and uses thereof
US10227408B2 (en) 2015-02-19 2019-03-12 Compugen Ltd. Anti-PVRIG antibodies and methods of use
EP3259597B1 (en) 2015-02-19 2022-04-06 Compugen Ltd. Pvrig polypeptides and methods of treatment
AU2016233495B2 (en) 2015-03-13 2022-02-24 Cytomx Therapeutics, Inc Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
JP6775516B2 (en) 2015-03-17 2020-10-28 ファイザー・インク Innovative 3-indole substituted derivatives, pharmaceutical compositions, and usage
KR102610592B1 (en) 2015-03-30 2023-12-07 주식회사 에스티큐브 Antibody specific for glycosylated PD-L1 and method of using the same
TW201705955A (en) 2015-05-14 2017-02-16 輝瑞大藥廠 Combination therapies comprising a pyrrolidine-2,5-dione IDO1 inhibitor and an anti-PD1/anti-PD-L1 antibody
TWI773646B (en) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 Lag-3-binding molecules and methods of use thereof
US10696745B2 (en) 2015-06-11 2020-06-30 Wuxi Biologics (Shanghai) Co. Ltd. Anti-PD-L1 antibodies
GB201511790D0 (en) 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
CA2993177A1 (en) 2015-07-22 2017-01-26 Sorrento Therapeutics, Inc. Antibody therapeutics that bind lag3
LT3317301T (en) 2015-07-29 2021-07-26 Novartis Ag Combination therapies comprising antibody molecules to lag-3
HUE055207T2 (en) 2015-07-30 2021-11-29 Macrogenics Inc PD-1 and LAG-3 binding molecules and methods for their use
CN106397592A (en) 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 Single-domain antibody directed at programmed death ligand (PD-L1) and derived protein thereof
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
JP2018526989A (en) 2015-08-07 2018-09-20 ピエリス ファーマシューティカルズ ゲーエムベーハー Novel fusion polypeptide specific for LAG-3 and PD-1
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
JP2018527336A (en) 2015-08-10 2018-09-20 ファイザー・インク 3-indole substituted derivatives, pharmaceutical compositions, and methods of use
AR105654A1 (en) 2015-08-24 2017-10-25 Lilly Co Eli ANTIBODIES PD-L1 (LINKING 1 OF PROGRAMMED CELL DEATH)
CN114605548A (en) 2015-09-01 2022-06-10 艾吉纳斯公司 anti-PD-1 antibodies and methods of use thereof
PT3354729T (en) 2015-09-24 2024-04-11 Daiichi Sankyo Co Ltd Anti-garp antibody
KR20180068990A (en) 2015-10-01 2018-06-22 포텐자 테라퓨틱스, 인코포레이티드 Anti-TIGIT antibody-binding proteins and methods for their use
TWI756187B (en) 2015-10-09 2022-03-01 美商再生元醫藥公司 Anti-lag3 antibodies and uses thereof
CN116003596A (en) 2015-10-29 2023-04-25 艾利妥 Anti-SIGLEC-9 antibodies and methods of use thereof
SG11201804178YA (en) 2015-11-18 2018-06-28 Merck Sharp & Dohme Pd1 and/or lag3 binders
US20190330336A1 (en) 2015-11-19 2019-10-31 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
WO2017106129A1 (en) 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
CA3011092A1 (en) 2016-01-12 2017-07-20 Palleon Pharmaceuticals Inc. Use of siglec-7 or siglec-9 antibodies for the treatment of cancer
US9624185B1 (en) 2016-01-20 2017-04-18 Yong Xu Method for preparing IDO inhibitor epacadostat
CN108029076B (en) 2016-02-02 2020-03-10 华为技术有限公司 Method, user equipment and base station for determining transmit power
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
WO2017173091A1 (en) 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
EP3848393A1 (en) 2016-05-18 2021-07-14 Boehringer Ingelheim International GmbH Antibody molecules for cancer treatment
JP6794442B2 (en) 2016-05-30 2020-12-02 アステラス製薬株式会社 New transgenic vaccinia virus
EP3472207B1 (en) 2016-06-20 2021-01-20 F-Star Delta Limited Binding molecules binding pd-l1 and lag-3
TW201831513A (en) 2016-06-20 2018-09-01 Ｆ星貝塔有限公司 Binding members
AU2017282892B2 (en) 2016-06-23 2023-10-26 Jiangsu Hengrui Medicine Co., Ltd. LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof
WO2018017864A2 (en) 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
US20190185571A1 (en) 2016-07-28 2019-06-20 Musc Foundation For Research Development Methods and compositions for the treatment of cancer combining an anti-smic antibody and immune checkpoint inhibitors
KR20190035863A (en) 2016-08-05 2019-04-03 알라코스 인크. Anti-Siglec-7 Antibody for Cancer Treatment
US11324744B2 (en) 2016-08-08 2022-05-10 Acetylon Pharmaceuticals Inc. Methods of use and pharmaceutical combinations of histone deacetylase inhibitors and CD20 inhibitory antibodies
MX2019001897A (en) 2016-08-15 2019-08-29 Univ Hokkaido Nat Univ Corp Anti-lag-3 antibody.
CN112274637A (en) 2016-08-17 2021-01-29 康姆普根有限公司 Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
WO2018054484A1 (en) * 2016-09-23 2018-03-29 Biontech Ag Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
TW202436356A (en) 2016-10-11 2024-09-16 美商艾吉納斯公司 Anti-lag-3 antibodies and methods of use thereof
PE20190911A1 (en) 2016-10-13 2019-06-26 Symphogen As ANTI-LAG-3 COMPOSITIONS AND ANTIBODIES
BR112019008861A2 (en) 2016-11-01 2019-07-09 Tesaro, Inc. antibodies directed against t-cell immunoglobulin and mucin 3 (tim-3) protein
WO2018083087A2 (en) 2016-11-02 2018-05-11 Glaxosmithkline Intellectual Property (No.2) Limited Binding proteins
JOP20190133A1 (en) 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd Anti-tim-3 antibodies for combination with anti-pd-1 antibodies
EP3551659A1 (en) 2016-12-08 2019-10-16 Eli Lilly and Company Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies
CN107058315B (en) 2016-12-08 2019-11-08 上海优卡迪生物医药科技有限公司 Knockdown of human PD-1 siRNA, recombinant expression CAR-T vector and its construction method and application
CA3046432A1 (en) 2016-12-13 2018-06-21 Astellas Pharma Inc. Anti-human cd73 antibody
CN109071656B (en) 2017-01-05 2021-05-18 璟尚生物制药公司 Checkpoint modulator antagonists
US20210340250A1 (en) 2017-05-30 2021-11-04 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
WO2019000146A1 (en) 2017-06-26 2019-01-03 深圳市博奥康生物科技有限公司 Sirna of human programmed cell death receptor 1 and use thereof
KR102677225B1 (en) 2017-07-10 2024-06-24 이나뜨 파르마 에스.에이. SIGLEC-9 neutralizing antibody
WO2019011852A1 (en) 2017-07-10 2019-01-17 Innate Pharma Combination therapy using antibody to human siglec-9 and antibody to human nkg2a for treating cancer
IL280467B2 (en) * 2018-08-03 2025-03-01 Amgen Res Munich Gmbh Antibody constructs for cldn18.2 and cd3
JP2022541435A (en) * 2019-07-17 2022-09-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Claudin-18 antibodies and methods of treating cancer
WO2021024020A1 (en) * 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
TW202304506A (en) * 2021-03-25 2023-02-01 日商安斯泰來製藥公司 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2022262959A1 (en) * 2021-06-15 2022-12-22 Astellas Pharma Europe Bv Bispecific binding agents binding to cldn18.2 and cd3

Also Published As

Publication number Publication date
AR131342A1 (en) 2025-03-12
CO2025009080A2 (en) 2025-07-28
EP4634224A1 (en) 2025-10-22
CL2025001604A1 (en) 2025-08-01
WO2024126457A1 (en) 2024-06-20
TW202436336A (en) 2024-09-16
KR20250120305A (en) 2025-08-08
CN120418289A (en) 2025-08-01
AU2023393653A1 (en) 2025-05-22
JP2026501506A (en) 2026-01-16
MX2025006378A (en) 2025-07-01

Similar Documents

Publication Publication Date Title
IL308072A (en) Bispecific binding agents binding to cldn18.2 and cd3
MX2023005375A (en) Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases.
MX2024013526A (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
IL290123A (en) Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
MY199655A (en) Dll3-cd3 bispecific antibodies
GB201912681D0 (en) Bispecific binding agent that binds to cd117/c-kit and cd3
ZA202006481B (en) Anti-msr1 antibodies and methods of use thereof
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
NZ707831A (en) Agents for treatment of claudin expressing cancer diseases
ATE473242T1 (en) THERAPEUTIC AGENTS CONTAINING A BISPECIFIC ANTI-HLA CLASS II INVARIANT CHAIN X ANTI-PATHOGEN ANTIBODIES
PH12013500826A1 (en) Means and methods for treating dlbcl
SA523440623B1 (en) Antibodies
PH12022551960A1 (en) Antibodies binding to b7h4
IL321098A (en) Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
MY202157A (en) Anti-pd-l1 antibody and use thereof
MX2022006533A (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof.
IL315526A (en) Ilt3 and cd3 binding agents and methods of use thereof
MX2022010021A (en) Pilra antibodies and methods of use thereof.
MX2025000569A (en) Cd98hc antigen-binding domains and uses therefor
MX2024000674A (en) Multispecific binding agents against cd40 and cd137 in combination therapy for cancer.
MX2020008718A (en) Bcma-binding antibodies and uses thereof.
IL309495A (en) Agents encoding CLDN6 and CD3 binding elements for the treatment of CLDN6-positive cancer
PH12022550006A1 (en) Cd38-binding agents and uses thereof
MX2020006125A (en) Use of a cea cd3 bispecific antibody and a pd-1 axis binding antagonist in a dosage regime to treat cancer.
MX2022005238A (en) Treatment of cancer using a hla-a2/wt1 x cd3 bispecific antibody and lenalidomide.